The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patients

BACKGROUND: There has been debate on the use of angiotensin-converting enzyme‑2 (ACE2) expression mediating pharmacotherapy in COVID-19 infected patients. Although it has been suggested that these drugs might lead to a higher susceptibility and severity of COVID-19 infection, experimental data sugge...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kimmenade, R. R. J., Belfroid, E., Hoogervorst-Schilp, J., Siebelink, H. J., Janssen, C. W., Pinto, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2021
Materias:
Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050813/
https://www.ncbi.nlm.nih.gov/pubmed/33860910
http://dx.doi.org/10.1007/s12471-021-01573-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050813/
https://www.ncbi.nlm.nih.gov/pubmed/33860910
http://dx.doi.org/10.1007/s12471-021-01573-8

Ejemplares similares